story of the week
Paclitaxel Plus Bevacizumab vs Paclitaxel as First-Line Treatment for HER2-Negative Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Paclitaxel Plus Bevacizumab or Paclitaxel as First-Line Treatment for HER2-Negative Metastatic Breast Cancer in a Multicenter National Observational Study
Ann. Oncol 2016 Jul 19;[EPub Ahead of Print], S Delaloge, D Pérol, C Courtinard, E Brain, B Asselain, T Bachelot, M Debled, V Dieras, M Campone, C Levy, W Jacot, V Lorgis, C Veyret, F Dalenc, JM Ferrero, L Uwer, P Kerbrat, A Goncalves, MA Mouret-Reynier, T Petit, C Jouannaud, L Van Lemmens, G Chenuc, T Guesmia, M Robain, C CailliotFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.